Opendata, web and dolomites


Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Total Cost €


EC-Contrib. €






 FrEBT project word cloud

Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.

economic    breath    gps    network       medical    innovative    fractional    disruptive    description    eu28    temperature    lives    14    doctors    markets    socio    commercial    bulgaria    launch    vulnerable    region    children    healthcare    market    solution    global    cancer    biomarker    population    filling    young    managerial    diseases    respiratory    assessing    oncology    deaths    total    organization    precise    lung    feasibility    faster    validate    risk    invasive    financial    clinical    prognostic    innovation    diagnosis    painful    niche    annually    inflammatory    stages    competitiveness    profitability    technological    12    asia    full    share    monitoring    service    elderly    20    phase1    worldwide    pulmonary    organizational    118    ltd    comac    obstructive    regions    groups    countries    bln    trials    saving    sme    specialists    specialisation    380    morbidity    exhaled    causing    alternative    diagnostic    pulmonology    ip    device    outcome    people    workforce    million    15    patients    mortality    prove    10    mln   

Project "FrEBT" data sheet

The following table provides information about the project.


Organization address
address: 131 ODRIN STR AP 22
city: SOFIA
postcode: 1303
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Bulgaria [BG]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMAC MEDICAL LTD BG (SOFIA) coordinator 50˙000.00


 Project objective

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  


Integrating and decentralising diabetes and hypertension services in Africa

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More